Get the Daily Brief
Latest Biotech News
Big pharma dealmaking for blood cancer pipeline
Eli Lilly agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash, securing a clinical-stage JAK2 inhibitor for myeloproliferative neoplasms. Ajax’s lead asset, AJ1-11095, is a Type II...
Regenerative diagnostics and platform commercialization
Nautilus Biotechnology reported narrower Q1 losses and began rolling out early access for its Voyager protein analysis platform. The Seattle-based company said it reduced its net loss to $14.7...
Precision diagnostics platform FDA progress in psychiatry
Laguna Diagnostics’ blood-based mRNA Gene Biomarker test for differentiating schizophrenia from bipolar I received FDA Breakthrough Device designation. The test, intended for use alongside...
Oncology: in vivo CRISPR nears FDA filing after Phase 3 win
Intellia reported Phase 3 success for its in vivo CRISPR therapy lonvo-z in hereditary angioedema, setting up regulatory steps toward potential FDA approval. The biotech said the therapy met its...
Company earnings and guidance: diagnostics demand headwinds
Qiagen lowered its full-year 2026 guidance after reporting preliminary Q1 net sales growth that missed expectations and remained pressured by external demand shifts. The company reported...
Autoimmune pipeline asset: Oruka’s psoriasis data
Oruka Therapeutics posted Phase 2 results for ORKA-001 in plaque psoriasis, reporting that 63% of patients achieved complete skin clearance at 16 weeks and that updated exposure data supports...
Procurement and reimbursement friction: prior authorization remains a bottleneck
Healthcare organizations are finding that digitizing medical policy and implementing FHIR APIs does not automatically solve prior authorization delays at scale. The issue is that medical-necessity...
Oncology: pancreatic and lung RAS inhibitor early clinical signals
Erasca released preliminary clinical data for ERAS-0015, reporting tumor shrinkage in subsets of patients with advanced pancreatic cancer and advanced non-small cell lung cancer. The company said...
Obesity drug pipeline: Boehringer’s survodutide posts Phase 3 weight-loss readout
Boehringer Ingelheim disclosed Phase 3 results for survodutide, reporting 16.6% mean weight loss after about a year of treatment, using a dual-agonist approach that targets GLP-1 and glucagon...
Oral in vivo gene editing: Intellia tees up FDA filing after Phase 3 hereditary angioedema win
Intellia reported Phase 3 success for its in vivo CRISPR medicine lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE), meeting the primary endpoint by reducing swelling attack rates 87%...
In vivo CRISPR momentum: Intellia files with FDA after lonvo-z hits Phase 3 HAE endpoint
Intellia said its lonvo-z CRISPR therapy achieved the primary endpoint in a Phase 3 trial for hereditary angioedema and has now moved toward an FDA submission. The biotech reported an 87%...
Big Pharma M&A: Eli Lilly buys Ajax Therapeutics for up to $2.3B to bolster JAK franchise
Eli Lilly announced it will acquire Ajax Therapeutics for up to $2.3 billion in cash, adding next-generation JAK biology for myeloproliferative neoplasms. The deal gives Lilly access to AJ1-11095,...
Genome engineering platform: Gladstone’s retron recombineering extends efficient editing beyond E. coli
Gladstone Institutes researchers reported a retron-based genome editing approach that works across diverse bacterial species beyond E. coli. The study, published in Nature Biotechnology, describes...
Immuno-oncology targets: AACR analyses surface 176 proposed new cancer targets
A BioCentury analysis of the nearly 7,000 abstracts at AACR 2026 identified 176 new oncology targets proposed for future therapies. The review emphasized immuno-oncology themes, including...
Autoimmune dermatology: Oruka’s IL-23 antibody posts strong Phase 2 psoriasis clearance rates
Oruka Therapeutics reported Phase 2a results for its long-acting IL-23 monoclonal antibody ORKA-001 in plaque psoriasis, with 40 of 63 patients achieving PASI 100 at 16 weeks and 83% reaching PASI...
Atrial fibrillation med-tech race: PFA data keep positioning ahead in Heart Rhythm update cycle
Pulmonary vein ablation competition intensified as new pulsed field ablation (PFA) data presented at Heart Rhythm 2026 continued to show clinical benefits and technology differentiation for...
Coronary artery disease biomarkers: PlaqueTec raises $5M to build intracoronary protein database
PlaqueTec raised $5 million in an oversubscribed financing round led entirely by existing investors, funding continued work on its BIOPATTERN clinical trial for coronary artery disease biomarkers....
Regulatory and access: New data show QC gaps after CDC testing pause – Wadsworth Center steps in
The New York State Department of Health’s Wadsworth Center said it is filling laboratory testing gaps triggered by the US Centers for Disease Control and Prevention’s pause on testing for multiple...
In vivo CRISPR gene editing moves to an FDA filing pathway
Intellia Therapeutics reported Phase 3 success for lonvo-z (lonvoguran ziclumeran) in hereditary angioedema (HAE), cutting swelling attack rates by 87% versus placebo over six months. In the...
Big Pharma doubles down on next-generation JAK inhibitors through Ajax acquisition
Eli Lilly agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash, adding a clinical-stage JAK2 inhibitor program for myeloproliferative neoplasms. Ajax’s lead asset, AJ1-11095, is a...